ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Kevin P. McRaith has joined the Company as Vice President, Hepatology Franchise. Mr. McRaith, formerly Vice President, Sales & Marketing - Hematology, Genentech Corporation, will report to Barry A. Labinger, Executive Vice President and Chief Commercial Officer.
"Kevin McRaith brings to HGS a wealth of experience and an established record of accomplishment in the successful commercialization of products in a number of therapeutic areas," said Mr. Labinger. "I am excited to have Kevin join our senior management team to play a key role in our efforts to build a world class commercial organization. As head of our Hepatology Franchise, Kevin will have responsibility for all marketing and sales activities for Albuferon, including leading our preparation for launch and managing the overall performance of our Albuferon business."
Mr. McRaith has more than 20 years of experience commercializing
therapies for infectious diseases, oncology, neurological diseases and
cardiology. As Vice President, Sales and Marketing for Genentech's
Hematology Franchise, he led the commercial efforts for the top-selling
biologic, Rituxan (rituximab). Prior to joining Genentech in 2005, Mr.
McRaith served with Abbott Laboratories for 15 years, where he held a
number of senior positions with responsibility for managing major product
franchises, directing marketing and sales activities, and leading a number
of successful launches. Before joining Abbott in 1990, he spent several
years in sales and
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved